According to Medifast's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.342299. At the end of 2023 the company had a P/S ratio of 0.6830.
Year | P/S ratio | Change |
---|---|---|
2023 | 0.6830 | -13.38% |
2022 | 0.7885 | -50.54% |
2021 | 1.59 | -35.51% |
2020 | 2.47 | 36.85% |
2019 | 1.81 | -39.01% |
2018 | 2.96 | 7.2% |
2017 | 2.76 | 53.76% |
2016 | 1.80 | 36.75% |
2015 | 1.31 | -13.46% |
2014 | 1.52 | 58.1% |
2013 | 0.9603 | -5.72% |
2012 | 1.02 | 43.28% |
2011 | 0.7109 | -58.92% |
2010 | 1.73 | -36.52% |
2009 | 2.73 | 263.31% |
2008 | 0.7503 | -5.46% |
2007 | 0.7936 | -65.05% |
2006 | 2.27 | 38.32% |
2005 | 1.64 | 15.9% |
2004 | 1.42 | -75.68% |
2003 | 5.82 | 87.58% |
2002 | 3.10 | 979.66% |
2001 | 0.2876 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
OPKO Health
OPK | 1.02 | 197.12% | ๐บ๐ธ USA |
Abeona Therapeutics
ABEO | 25.7 | 7,412.06% | ๐บ๐ธ USA |
Bellerophon Therapeutics
BLPH | 0.1202 | -64.90% | ๐บ๐ธ USA |